Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pki-166. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pki-166 SCHEMBL185822 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL30883827 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL29352405 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL9973098 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL29409570 | 0.99 | EGFR (0.98) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL12308303 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4766235 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4766237 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL7499430 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4901987 | 0.89 | EGFR (1.00) | EGFRHDAC3KDRHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207805-B1 | NLRR-1 ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| US-20090221519-A1 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| CN-101035540-A | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | claimed |
| EP-1553950-B1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | claimed |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | claimed |
| US-20030125343-A1 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound | GAMBACORTI-PASSERINI CARLO (IT) | 2003-07-03 | — | — | US | claimed |
| WO-2003037897-A2 | USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN THE TREATMENT OF SOLID TUMOR DISEASES | NOVARTIS AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-20030065000-A1 | Method of treating cancer | COHEN PAMELA SARAH (US) | 2003-04-03 | — | — | US | claimed |
| EP-1250140-A2 | COMBINATIONS OF A RECEPTOR TYROSINE KINASE INHIBITOR WITH ALPHA1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | Novartis AG (CH) | 2002-10-23 | — | — | EP | claimed |
| WO-2002050306-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-27 | — | — | WO | claimed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221519-A1 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | PDGFRA, PDGFRB, TEK | EGFR 22/4885CSF1R 57/4885HDAC3 4594/4885 |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885CSF1R 645/4885HDAC3 3897/4885 |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885CSF1R 350/4885HDAC3 1941/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | EGFR 53/4885CSF1R 2553/4885HDAC3 3882/4885 |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BPHL, EGFR, ERBB3 | EGFR 2/4885CSF1R 350/4885HDAC3 1941/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885CSF1R 2574/4885HDAC3 3515/4885 |
| US-20030125343-A1 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound | PDGFRA, PDGFRB, TEK | EGFR 23/4885CSF1R 58/4885HDAC3 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.